<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pathogens-08-00176-t003" orientation="portrait" position="float">
 <object-id pub-id-type="pii">pathogens-08-00176-t003_Table 3</object-id>
 <label>Table 3</label>
 <caption>
  <p>Viral and clinical response after antiviral therapy with DAAs in patients with HCV-associated GN.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"> </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">DAAs</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SVR12</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Complete Clinical Response</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Partial Clinical Response</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Concomitant IS</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gragnani L, et al. (2016) (
     <italic>n </italic>= 4)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF-based regimen</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4(100%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3(75%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1(25%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1(25%)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sise M, et al. (2016) (
     <italic>n </italic>= 7)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF+SIM (
     <italic>n </italic>= 6)
     <break/>SOF+RBV (
     <italic>n </italic>= 1)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6(86%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3(43%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4(57%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2(29%)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saadoun D, et al. (2016) (
     <italic>n </italic>= 5).
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF+RBV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4(80%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4(80%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2(40%)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sollima S, et al. (2016) (
     <italic>n </italic>= 5)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF+RBV
     <break/>SOF+DCV
     <break/>SOF+SIM
     <break/>3D
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5(100%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1(20%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emery J, et al. (2017) (
     <italic>n </italic>= 10)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF+RBV
     <break/>SOF+SIM
     <break/>3D±RBV
     <break/>SOF+LDV±RBV
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7(70%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2(20%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2(20%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4(40%)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saadoun D, et al. (2017) (
     <italic>n </italic>= 5)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF+DCV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5(100%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3(60%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1(20%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bonacci M, et al. (2018) (
     <italic>n </italic>= 9)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF-based regimen±RBV
     <break/>3D±RBV
     <break/>SIM+DCV
     <break/>GZR+EBR
     <break/>pegIFN+DAAs
     <break/>FDV+DLR
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9(100%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6(67%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3(33%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5(55%)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fabrizi F, et al. (2018) (
     <italic>n </italic>= 13)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF+RBV (
     <italic>n </italic>= 6)
     <break/>3D+RBV (
     <italic>n </italic>= 4)
     <break/>SOF+LDV (
     <italic>n </italic>= 1)
     <break/>SOF+DCV+RBV (
     <italic>n </italic>= 2)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13(100%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3(23%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7(54%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9(69.2%)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Obrisca B, et al. (2019) (
     <italic>n </italic>= 9)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3D</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9(100%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2(23%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1(10%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6(67%)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>3D+ribavirin (RBV), ritonavir-boosted paritaprevir/ombitasvir/dasabuvir with or without RBV; EBR, elbasvir; FDV, faldaprevir; GRZ, grazoprevir; LDV, ledipasvir; PegIFN, pegylated interferon; SIM, simeprevir, SOF, sofosbuvir.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
